Proxygen is a Vienna-based startup that develops therapies against cancer and other life-threatening diseases by reprogramming the cellular protein quality control system. We are focused on particular small molecules called “molecular glue degraders” which mediate recruitment of a disease-causing protein to a ubiquitin ligase. Consequently, the target protein is ubiquitinated and directed to the proteasome for degradation. Hence, instead of merely blocking the function of harmful proteins, molecular glue degraders enable their complete, targeted and selective elimination. This outlines a clear avenue towards targeting otherwise undruggable proteins and is therefore seen as one of the most promising innovations of the last decades.